OGEN vs. XCUR, ALZN, SEEL, KA, SONN, CPHI, ATXI, GTBP, SNPX, and VCNX
Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Exicure (XCUR), Alzamend Neuro (ALZN), Seelos Therapeutics (SEEL), Kineta (KA), Sonnet BioTherapeutics (SONN), China Pharma (CPHI), Avenue Therapeutics (ATXI), GT Biopharma (GTBP), Synaptogenix (SNPX), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical preparations" industry.
Exicure (NASDAQ:XCUR) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
42.8% of Exicure shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 8.4% of Exicure shares are owned by insiders. Comparatively, 24.6% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Exicure has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
In the previous week, Oragenics had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Oragenics and 2 mentions for Exicure. Oragenics' average media sentiment score of 0.46 beat Exicure's score of 0.00 indicating that Exicure is being referred to more favorably in the media.
Exicure received 9 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 47.37% of users gave Exicure an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
Oragenics' return on equity of 0.00% beat Exicure's return on equity.
Exicure has higher revenue and earnings than Oragenics. Oragenics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.
Summary
Exicure beats Oragenics on 11 of the 14 factors compared between the two stocks.
Get Oragenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oragenics Competitors List
Related Companies and Tools
